| 前收市價 | 20.61 |
| 開市 | 20.72 |
| 買盤 | 0.00 x 1100 |
| 賣出價 | 20.95 x 1100 |
| 今日波幅 | 20.63 - 21.04 |
| 52 週波幅 | 17.75 - 24.27 |
| 成交量 | |
| 平均成交量 | 1,065,641 |
| 市值 | 19.044B |
| Beta 值 (5 年，每月) | 0.78 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.51 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2022年5月12日 |
| 1 年預測目標價 | 20.68 |
ZacksPhilips' (PHG) Zenition 30 to Boost Image-Guided Surgeries
Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.
ZacksPhilips (PHG) Agrees to a Consent Decree With DOJ and FDA
Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.
- Reuters
US federal court orders Philips to restrict production of sleep apnea devices
(Reuters) -A U.S. federal court issued a decree to restrict the production and sale of Philips' new sleep apnea machines at several facilities in the country, the Food and Drug Administration said on Tuesday. The U.S. District Court for the Western District of Pennsylvania has entered into what is known as a consent decree against the company's subsidiary Philips Respironics to curb the sale and production until certain requirements are met. In January, the Dutch health technology company had said that it will not sell new devices to treat sleep apnea in the United States in the coming years as it works to comply with a settlement with the FDA.
